MarginsXMarginsX
Home › Markets › Health Care › EQ

Equillium Inc. (EQ)

EQ trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.15
-10.85% on the day
Market cap
$94.7M
Micro cap
Revenue · 2024
$41.1M
+13.9% on 2023
Net income · 2024
-$8.1M
-19.6% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1746466/000119312526124143/0001193125-26-124143-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerEQ on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2018
SEC CIK0001746466
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$41.1M
Net income-$8.1M
Operating income-$8.3M
Net margin-19.6%
Operating margin-20.1%
Revenue growth+13.9%
Cash$18.1M
Total assets$25.6M
P/E (computed)Net income was not positive
P/S (computed)2.3×

Warning signs

Cash runway
41.6 months
$53.3M cash at September 30, 2026
Share count, 1 year
+35.2%
2025-11-10 to 2026-11-10 · +134.4% over 3 years
Going-concern doubt
No
10-Q filed November 12, 2026
Insider net buying, 12 months
-$2.4M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-12
Cash and burn$53.3M cash; operating cash flow -$3.8M a quarter.Report 2026-09-30
Shares outstanding82,324,700 (2026-11-10); 60,893,283 a year earlier; 35,119,248 three years earlier.Cover page 2026-11-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-11-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCrowe LLP, Costa Mesa, California, United States; changed auditors 2 times in 24 months8-K 4.01 2025-10-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $2.4M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$4.6M-$3.8M$53.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
Not filed-$4.7M-$4.1M$57.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2026
2026-03-31
Not filed-$5.3M-$4.3M$61.3MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2025
2025-12-31
Not filed-$3.8M-$3.1M$30.3MNo debt tagsNeeds four quarters10-K 2026-03-25
Q3 2025
2025-09-30
Not filed-$4.2M-$8.4M$33.1MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2025
2025-06-30
Not filed-$5.7M-$3.0M$11.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q1 2025
2025-03-31
Not filed-$8.7M-$8.2M$14.5MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q4 2024
2024-12-31
$4.4M-$5.8M-$3.3M$18.1MNo debt tags$41.1M10-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-11-12
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-15

Source: SEC EDGAR submissions feed, 471 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-14.6%
1 month-2.3%
3 months-35.8%
Year to date-16.8%
1 year+53.6%
From 52-week high-59.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
NRXPNRX Pharmaceuticals Inc.$2.15-1.83%$93.8M
NBPNovaBridge Biosciences$0.7915-6.87%$91.3M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
OGIOrganigram Global Inc. Common Shares$0.7240-12.62%$102.2M
CUECue Biopharma Inc.$14.10-12.53%$102.4M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier